Song Li, MS, Senior R&D director, responsible for R&D of antibody drug
Song Li has over 8 years experience in antibody drug discovery and process development. He has much expertise in discovering lead candidates, in antibody engineering and optimization, in cell line and process development, and in extensive characterization of antibody activity.
2004.9-2008.7 studied at Inner Mongolia University of Science & Technology with a Bachelor of Biological Sciences. In 2008.9-2011.7, he studied at the College of Life Sciences of Jilin Agricultural University and obtained a Master degree in biochemistry and molecular biology. From September 2009 to March 2011, he completed his graduation project at Beijing Chest Hospital, Capital Medical University. From 2011.8 to 2012.4, he worked as a researcher at Shenzhen Yidakai Biotechnology Co., Ltd., responsible for molecular cloning and protein prokaryotic expression. From 2012.4 to 2015.12, he worked as a manager at Huabo Biopharm (Shanghai) Co., Ltd., responsible for drug in vitro function, cell line construction and molecular cloning. Since 2015.12, he has been working as the R&D director of Immuneonco Biopharm (Shanghai) Co., Ltd., and is responsible for the research and development of the company's projects.